Prosecution Insights
Last updated: April 19, 2026
Application No. 18/256,489

COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF

Final Rejection §DP
Filed
Jun 08, 2023
Examiner
SHIAO, REI TSANG
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Société des Produits Nestlé S.A.
OA Round
2 (Final)
80%
Grant Probability
Favorable
3-4
OA Rounds
2y 3m
To Grant
45%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allow Rate
1612 granted / 2019 resolved
+19.8% vs TC avg
Minimal -35% lift
Without
With
+-35.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
53 currently pending
Career history
2072
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
29.1%
-10.9% vs TC avg
§102
8.1%
-31.9% vs TC avg
§112
29.6%
-10.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 2019 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Priority and Status of Claims 1. This application is a 371 of PCT/EP2021/084588 12/07/2021, which claims benefit of the foreign application EPO EP20212799.9 with a filing date 12/09/2020. 2. Amendment of claims 1, 5-6, 9-11, and 13-14, cancelation of claims 2-4 and 15, and addition of claims 16-24 in the amendment filed on 2/6/2026 is acknowledged. Claims 1, 5-14 and 16-24 are pending in the application. No new matter has been found. Since the newly added claims 16-24 are commensurate within the scope of invention, claims 1, 5-14 and 16-24 are prosecuted in the case. Responses to Amendments/Arguments 3. The rejection of claims 1 and 5-14 under 35 U.S.C. 112 (a) has been overcome in the amendment filed on 2/6/2026. Since claims 2-4 have been canceled, therefore the rejection of claims 2-4 under 35 U.S.C. 112 (a) has been obviated herein. Since claim 3 has been canceled, therefore the rejection of claim 3 under 35 U.S.C. 112 (b) has been obviated herein. 4. Since De Luca et al. and Thiruvengadam et al. ‘636 do not disclose the instant methods of use, therefore they are distinct from the instant invention. The rejection of claims 1 and 5-10 under 35 U.S.C. 103 (a) has been overcome in the amendment filed on 2/06/2025. Since claims 2-3 have bee canceled, therefore the rejection of claims 2-3 under 35 U.S.C. 103 (a) has been obviated herein. 5. Since a terminal disclaimer against Feige et al. ‘914 has been filed to the Office, therefore the rejection of claims 1, 11 and 14 under the obviousness-type double patenting over Feige et al. ‘914 is maintained. Applicants are requested to file a terminal disclaimer to the Office. Claim Objections 6. Claims 5-10, 12-13 and 16-24 are objected to as being dependent on rejected claim 1. 7. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REI TSANG SHIAO whose telephone number is (571)272-0707. The examiner can normally be reached on 8:30 am-5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REI TSANG SHIAO/ Rei-tsang Shiao, Ph.D.Primary Examiner, Art Unit 1691 March 09, 2026
Read full office action

Prosecution Timeline

Jun 08, 2023
Application Filed
Nov 17, 2025
Non-Final Rejection — §DP
Feb 06, 2026
Response Filed
Mar 09, 2026
Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599580
COMPOSITION COMPRISING A LIPID COMPOUND, A TRIGLYCERIDE, AND A SURFACTANT, AND METHODS OF USING THE SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12600719
SALT INDUCIBLE KINASE INHIBITORS
2y 5m to grant Granted Apr 14, 2026
Patent 12599579
COMPOSITIONS AND COMPOUNDS CONTAINNG KETONE BODIES AND/OR KETONE BODY PRECURSORS AND ONE OR MORE AMINO ACIDS
2y 5m to grant Granted Apr 14, 2026
Patent 12595556
MOLYBDENUM IMIDO ALKYL/ALLYL COMPLEXES FOR DEPOSITION OF MOLYBDENUM-CONTAINING FILMS
2y 5m to grant Granted Apr 07, 2026
Patent 12594254
INTRANASAL ADMINISTRATION OF N-ACETYLCYSTEINE AND USES THEREOF
2y 5m to grant Granted Apr 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
80%
Grant Probability
45%
With Interview (-35.0%)
2y 3m
Median Time to Grant
Moderate
PTA Risk
Based on 2019 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month